Helus Pharma's HLP004 anxiety data arrive via promotional release, not a trial disclosure
A stock-promotion piece, not Cybin's CYB004 readout it was tracked against, carries the only HAM-A numbers on record for HLP004 in generalized anxiety disorder.
Executive Summary
- A Phase 2 generalized anxiety disorder catalyst that was supposed to report Cybin's CYB004 data instead surfaced HAM-A and remission figures attributed to a different company's drug, HLP004, through a promotional release rather than a company results disclosure.
- The trial actually being tracked, Cybin's randomized, double-blind CYB004 study, has not posted results on the public registry, so the numbers now associated with this catalyst trace to a different sponsor and a different asset entirely.
- The reported effect sizes carry no confidence intervals, p-values, or placebo-comparison detail, and arrive bundled inside a news-commentary piece built around an unrelated multibillion-dollar acquisition, undercutting how much weight the figures can bear.
- Generalized anxiety disorder now carries a modality-diverse Phase 2 and Phase 3 field of small-molecule and non-drug candidates, none of which shares a disclosed target with either CYB004 or HLP004, leaving both programs without a same-mechanism precedent to benchmark against.
What was supposed to happen
Cybin Inc. completed enrollment of 36 participants in its Phase 2 CYB004-002 study in generalized anxiety disorder in September 2025 and reaffirmed guidance for topline data in the first quarter of 2026. The registered primary endpoint is change in the Hamilton Anxiety Rating Scale (HAM-A) score from baseline at six weeks after the first of two intramuscular CYB004 administrations, with a secondary endpoint tracking HAM-A through the double-blind period at week 12. The trial randomized participants 2:1 between a 20 mg dose predicted to be therapeutic and a 2 mg dose predicted to be sub-therapeutic, run under quadruple masking with 36 patients total. Cybin's interim CEO, Eric So, said at enrollment completion that the company looked forward to sharing topline data in the first quarter of 2026. Cybin+1Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety DisorderSep 8, 2025A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)NCT06051721
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What actually surfaced
No results have posted against NCT06051721. Instead, a July 17, 2026 news-commentary release issued on behalf of Helus Pharma reported that its own drug, HLP004, described as a deuterated DMT candidate for generalized anxiety disorder, produced an average improvement of more than 10 points on the HAM-A by week six in a 36-patient Phase 2 study, with 67% responders and 39% in remission in the pooled population at six months and no drug-related serious adverse events. The release frames this HLP004 result as one bullet point inside a piece principally about Eli Lilly and Company's agreement to acquire AtaiBeckley Inc. for up to $3.8 billion, and it explicitly discloses that it was issued on behalf of Helus Pharma. NCT06051721+1A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)NCT06051721Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimeJul 17, 2026
Why the source matters
A HAM-A improvement of more than 10 points and a 67% responder rate would be clinically notable figures in generalized anxiety disorder if they came from a company results disclosure with a stated comparator, confidence interval, and registered analysis population. Here they come from a promotional commentary piece bundled with an unrelated acquisition story and carrying no p-value, no placebo or comparator arm breakdown, and no citation to a completed trial record. The release itself is the only place these HLP004 figures appear. BigBig Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimeJul 17, 2026
The registered trial's own record
Cybin's CYB004 study moved its primary completion date twice, from September 2024 to November 2024 and then to October 14, 2025, and its status shifted to Active, not recruiting on the same day the completion date was revised, October 27, 2025. Enrollment held flat at its target of 36 participants throughout, which the trial's own operational baseline treats as a routine pattern rather than a shortfall. The study's overall completion date is listed as September 1, 2026, later than the guided Q1 2026 topline-data window, which is consistent with why a public results posting for CYB004 itself has not appeared. NCT06051721A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)NCT06051721
The competitive field
Generalized anxiety disorder currently carries Phase 2 and Phase 3 programs spanning small-molecule 5-HT2A and TAAR1 agents, such as Definium Therapeutics' MM120 and Otsuka's ulotaront, alongside non-drug modalities including digital therapeutics and neurostimulation devices. None of the sourced comparators shares a disclosed target with CYB004 or HLP004, and the field's own risk baseline classifies the indication's active trials as low-to-medium operational risk with no single program among them yet holding a posted efficacy result. Five drugs are approved for GAD in the United States, including duloxetine, paroxetine, buspirone, and alprazolam, all through established antidepressant or anxiolytic mechanisms rather than psychedelic-class compounds.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.